Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3766096 | 0.99 | AR (0.57) | ARFAAHL3MBTL1NPC1RAB9A | |
| SCHEMBL1259386 | 0.84 | SMN1; SMN2 (0.61) | ARFAAHL3MBTL1NPC1RAB9A | |
| SCHEMBL194798 | 0.81 | L3MBTL1 (0.72) | ARL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3774648 | 0.80 | FAAH (0.62) | ARFAAHL3MBTL1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3766425 | 0.80 | L3MBTL1 (0.70) | ARL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3777109 | 0.80 | L3MBTL1 (0.70) | ARL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15269497 | 0.79 | AR (0.52) | ARFAAHL3MBTL1NPC1RAB9A | |
| SCHEMBL3765936 | 0.79 | AR (0.56) | ARFAAHL3MBTL1NPC1RAB9A | |
| SCHEMBL3759712 | 0.79 | MAPT (0.54) | ARFAAHL3MBTL1NPC1RAB9A | |
| SCHEMBL18204121 | 0.78 | AR (0.54) | ARNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | AR 2900/4885FAAH 1/4885L3MBTL1 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.